This clinical trial is focused on studying the long-term effects of a treatment for a condition called Retinopathy of Prematurity (ROP). ROP is an eye disease that affects premature infants, potentially leading to vision problems. The treatment being evaluated in this study is a medication called Eylea, which is a solution for injection containing the active substance Aflibercept. This medication is administered through an injection into the eye, a method known as intravitreal use.

The purpose of this study is to assess the long-term outcomes in children who previously received treatment for ROP in an earlier study. Researchers aim to evaluate the children’s visual acuity, which refers to the clarity or sharpness of vision, and to monitor the safety of the treatment over time. The study will also look at other aspects of eye health and development, such as the structure of the eye and neurodevelopmental outcomes, which involve the development of the brain and nervous system.

Participants in this study will be monitored over a period of time to gather information on their vision and overall health. The study will help determine how effective and safe the treatment is in the long run for children who have been affected by ROP. This information is crucial for understanding the potential benefits and risks of using Eylea in treating this condition.